Exhibit 99.1


CollPlant Overview H.C. Wainwright 23 rd Annual Global Investment Conference Se p t ember 2021



Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions . We intend these forward - looking statements to be covered by the safe harbor provisions for forward - looking statements contained in Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions . These forward - looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made . Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward - looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved . Furthermore, actual results may differ materially from those described in the forward - looking statements and will be affected by a variety of risks and factors that are beyond our control . Risks and uncertainties for our company include, but are not limited to : the Company’s history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all ; the Company’s expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG ; the Company’s ability to obtain favorable pre - clinical and clinical trial results ; regulatory action with respect to rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling ; commercial success and market acceptance of the Company’s rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG ; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers ; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations ; the Company’s reliance on third parties to conduct some or all aspects of its product manufacturing ; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual property rights of others ; the overall global economic environment ; the impact of competition and new technologies ; general market, political, and economic conditions in the countries in which the Company operates ; projected capital expenditures and liquidity ; changes in the Company’s strategy ; and litigation and regulatory proceedings . Many of these factors that will determine actual results are beyond our ability to control or predict . For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward - looking statements, see the “Risk Factors” section of included in our most recently filed Annual Report on Form 20 - F . Existing and prospective investors are cautioned not to place undue reliance on these forward - looking statements, which speak only as of the date hereof . The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change . Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward - looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise . While we may elect to update these forward - looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law . The trademarks included herein are the property of the owners thereof and are used for reference purposes only . Such use should not be construed as an endorsement of such products .



3 CollPlant – Unlocking the Regenerative Potential of rhCollagen Collaboration Agreements with Industry Leaders • AbbVie (ABBV) - Worldwide exclusive agreement for dermal and soft tissue fillers. Up to $103mm in payments plus royalties. • 3 D S ystems ( DDD ) - Bioprinted solutions for breast reconstruction treatments Well Capitalized $48mm in cash and equivalents (June 30, 2021) Regenerative and Aesthetic Medicine Company Developing innovative technologies and products for tissue regeneration and organ manufacturing, to help people live longer and better P r o p ri e t a ry Pla n t - b a sed Technology Platform Only commercially viable solution for mass production of rhCollagen



Our body is made of collagen ~30% of body’s protein content Main structural protein in the extracellular matrix (e.g. cartilage, bones, tendons, ligaments, skin and vasculature) Ideal scaffolding molecule for regenerative medicine



5 Expressing 5 human genes Transgenic tobacco plants



Medical ae s t he t i c s Bi o I n k Commercial products (EU) rhCollagen production process Products rhCollagen G r owi n g Extraction Purification T r ans g e n i c t o b ac c o Cr ude e xt r act Plant - based platform produces human collagen in mass - scale



Better bio - functionality ● Accelerates human cell proliferation ● Faster tissue healing Superior homogeneity ● Controlled physical/rheological properties ● Reproducibility ● Transparency (not visible) Improved safety and greater purity ● Non - immunogenic ● Non - allergenic ● No pathogens ● No foreign body response rhCollagen - Ideal building block for tissue and organ transplants used in regenerative medicine Clear advantages over tissue - extracted collagen 7 Tissue Extracted Cell binding domains Cell binding domains Plant - derived



Product Pipeline Aesthetic medicine 3D bioprinting Dermal/soft tissue fillers BioInk formulations P h o t o c u ra b le dermal filler I n je ctab l e b reast implants Soft and hard tissues C ol l a b o ra t i o n with 3D bioprinted products Breast implants Regenerative Tissue Matrix for breast reconstruction



9 Collagen platform drives diverse opportunities for value creation Organs & Tissues • Breast im p la n ts* • P h o t o c u ra b le fillers Regenerative and aesthetic medicine applications 3D models for drug discovery and tissue testing Development mode Value creation Co - developed Internally - developed r hC ol l a g en sales Technology In - licensing • Mi l est o n e p ay m ents • Sales royalties • rhCollagen sales Mi l est o n e p ay m ents Sales royalties Pro du ct Sa les * injectable, bioprinted and Regenerative Tissue Matrix B i o I n k s rhCollagen



Dermal/Soft Tissue Fillers



Dermal fillers market overview ~2.2 M HA procedures in 2019 in the US 1 >$6.2B, 7.6% CAGR Global dermal filler market, 2019 2 CAGR 2020 - 2026 2 $100 - $250/unit Cost per syringe 3 11 1. 2. 3. https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic - surgery - statistics - full - report - 2019.pdf https:// www.gminsights.com/industry - analysis/dermal - filler - market https://www.medicalsparx.com/juvederm - hydrate , https://www.medicalsparx.com/buy - juvederm - ultra - plus - xc Hyaluronic acid 80% 2019 Procedure breakdown, U.S (by material) 1 Polymethyl methacrylate microspheres 1% F at 2 % Polylactic acid 4% PRP 5 % Calcium Hydroxylapatite 8.2%



12 Collaboration agreement with AbbVie (Feb. 2021) Agreement highlights: A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market Financial highlights: Up to $103M in potential payments, including: • $1 4 M u p f r on t p a yme n t • Up to $89 milestones and option payments Combines CollPlant’s proprietary rhCollagen technology and AbbVie's technology First right of negotiation for technology in an injectable breast implant and photocurable dermal filler CollPlant will manufacture and sell to AbbVie the rhCollagen used in the products Royalties on products sales



rhCollagen - based photocurable regenerative dermal filler key attributes I n jec t ion Sculpting Photocuring in - situ Tissue regeneration http://collplant.com/products/photocurable - dermal - filler - animation - video/ Good tissue retention Sculpting before curing Easy injection (30G needle) Optimized post curing stiffness



Injectable breast implants* 14 • Composed of rhCollagen, additional materials and fat cells taken from the patient • Intended to promote breast tissue regeneration • Designed to support the viability and function of the autologous fat cells, and to attract cells to promote tissue regeneration • The scaffold is designed to gradually degrade and be replaced by newly grown natural breast tissue that is free of any foreign material * AbbVie’s Option Product



3D Bioprinted Tissues and Organs



16 A great medical need for supply of life saving organs ~30,000 US transplants per year 115,000 US waiting list 900,000 US deaths per year from organ impairment 3D bioprinting expected to bridge this gap and allow unlimited supply of life saving organs The technological building blocks already exist – a system integrator is needed to assemble them all together CollPlant’s rhCollagen - based BioInks portfolio and biomaterials expertise, are ideal for tissue and organ manufacturing



17 In - house D e v e lopme n t Co llabo r at ion with tier - 1 De vel op m ent c os t Time to market Tiss u e s ● Br e a s t ● H e art valve ● C o r n e a ● S k i n ● Cart i l a g e En d ocr ine gl a n d s ● Ovary ● Pancreas ● Thyroid Organs ● Lungs ● K idne y ● Liver ● Heart Scaffolds ● Spine fusion ● T end o ns , lig ame n ts ● Bones ● Nerve conduits D r u g disc o v ery ● Drug screening ● Tissue testing ● Patient specific 3D bioprinting represents a wide range of development opportunities



rhCollagen BioInk compositions in development Direct Ink Writing (DIW) I n k j e t Projection S t e r eol i t ho g r ap h y Laser Induced Forward Transfer (LIFT) Polymers (p hy si c al p r o p erties) Ceramics (h a r d tissue) Nanoparticles ( s u s t ai n ed r elease/ p hy si c al p r o p ertie s ( ECM components (biological/ physical properties)



Breast Reconstruction / Augmentation



Provide extra coverage, direct - to - implant reconstruction and su p erior c o s m e t ic resu l ts U S : m o s t ly hu man - sourced (93%) EU : m o s t ly a n imal - sourced Used in 61% of U.S. breast reconstruction surgeries Breast reconstruction procedures using ADMS /yr (US): 60K Market p o t e n tial ( U S) $600Mn Surgical matrixes derived from cadavers and animals are associated with high costs, supply shortage and batch - to - batch variability 20 rhCo ll a g e n - b ased regenerative tissue matrix Regenerative Tissue Matrix (RTM) Developed in collaboration with 3D Systems



Breast implants market overview Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it. $1.4B Market w o rl d wi d e (2018 ) 1 $ 5 - 10K Cost per full procedure in US 2 ~2,500,000 Brea s t impl a n t p ro c ed u res W W (2019) 3 ~550,000 in U S (201 9 ) 4 FDA alert: Patients with breast implants have an increased risk of developing breast implant Associated - Anaplastic Large Cell Lymphoma (Feb 2019) 5 21 1. 2. 3. 4. 5. Analytical Research Cognizance, Global Breast Implant Market, March 2019 https://www.webmd.com/beauty/cosmetic - procedures - breast - augmentation#1 https://www.isaps.org/wp - content/uploads/2020/12/Global - Survey - 2019.pdf https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic - surgery - statistics - full - report - 2019.pdf \ https://www.fda.gov/medical - devices/letters - health - care - providers/breast - implant - associated - anaplastic - large - cell - lymphoma - bia - a lcl - letter - health - care - providers Procedure (US segmentation) 60% Breast augmentation 21% Breast Lift 19% Breast r e co n s tr u ction



* ECM - extracellular matrix 22 CollPlant’s 3D bioprinted breast implants Breast scaffold bioprinting ECM* components + autologous fat cells loading Impla n t a tion a n d vascularization Implant replacement by newly formed tissue



23 Product pipeline Product Dermal filler (AbbVie) rhCollagen BioInks Regenerative Tissue Matrix (with DDD) Photocurable dermal filler Injectable breast implant Breast implants (3D printed) Next milestone According to plan 1 st BioInk market launch expected Q4, 2021 Preclinical package Preclinical package Preclinical package Preclinical package



Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (N AS D AQ) & G am ida E&Y Ilana Belzer, PhD COO BioHarvest P roco g n i a L t d. O m ri x B ioph a r m a ceu t ic a l s Interpharm Nadav Orr, PhD VP R&D E t h i co n B iosur g ery , Johnson & Johnson 24 Philippe Bensimon, PharmD VP RA/QA/CA M a qu e t Ge t in ge 3M Medical Experienced management team Hadas Dreiher - Horowitz VP HR Elbit Teva Pharmaceuticals Mul - T - Lock



CollPlant investment thesis Only commercially viable technology currently available that can produce truly human collagen Multi - billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics Broadly applicable technology: Ideal building block/scaffolding molecule for regenerative medicine Strategic agreement with AbbVie and 3D Systems Clinically validated technology Proven management team 25



Thank you